Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 16/20 | 0.78 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7212097 | 0.88 | PTGS2 (1.00) | PTGS2PTGER1PTGS1KDM4EALDH1A1 | |
| SCHEMBL3035286 | 0.87 | PTGS2 (0.59) | PTGS2PTGS1 | |
| SCHEMBL6279269 | 0.86 | PTGS2 (0.54) | PTGS2KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL7210644 | 0.85 | PTGS2 (0.78) | PTGS2PTGER1PTGS1KDM4EALDH1A1 | |
| SCHEMBL5309102 | 0.85 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL6517559 | 0.85 | PTGS2 (0.89) | PTGS2PTGER1PTGS1KDM4EALDH1A1 | |
| SCHEMBL3026333 | 0.85 | PTGS2 (0.78) | PTGS2PTGER1PTGS1KDM4EALDH1A1 | |
| SCHEMBL7215254 | 0.85 | PTGS2 (0.78) | PTGS2PTGER1PTGS1KDM4EALDH1A1 | |
| SCHEMBL3035294 | 0.85 | PTGS2 (0.88) | PTGS2PTGER1PTGS1KDM4EALDH1A1 | |
| SCHEMBL3831175 | 0.85 | PTGS2 (1.00) | PTGS2PTGER1PTGS1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949536-B2 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | PFIZER, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040157824-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | PFIZER INC. | 2004-08-12 | — | — | US | disclosed |
| EP-1086097-B1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER (US) | 2004-05-19 | — | — | EP | disclosed |
| US-6727238-B2 | CYCLOOXYGENASE INHIBITORS | PFIZER INC. | 2004-04-27 | — | — | US | disclosed |
| US-20030225064-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | ANDO KAZUO (JP) | 2003-12-04 | — | — | US | disclosed |
| US-6608095-B2 | Sulfonylbenzene and sulfonamidobenzene compounds which inhibit COX-2; treatment of a medical condition in which prostaglandins are implicated as pathogens | PFIZER INC. | 2003-08-19 | — | — | US | disclosed |
| US-20020045654-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | ANDO KAZUO (JP) | 2002-04-18 | — | — | US | disclosed |
| US-6294558-B1 | ANTIINFLAMMATORY AGENTS AND PROSTAGLANTINS | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157824-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | CNR1, PTGS1, PTGER1 | PTGS2 29/4885PTGER1 3/4885PTGS1 2/4885 |
| US-20020045654-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | CNR1, PTGER1, PTGS1 | PTGS2 30/4885PTGER1 2/4885PTGS1 3/4885 |
| US-20030225064-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | CNR1, PTGS1, PTGER1 | PTGS2 29/4885PTGER1 3/4885PTGS1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.